Short Interest in Bioxytran, Inc. (OTCMKTS:BIXT) Decreases By 13.9%

Bioxytran, Inc. (OTCMKTS:BIXT) saw a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 6,200 shares, a decline of 13.9% from the February 13th total of 7,200 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 164,300 shares, the days-to-cover ratio is presently 0.0 days.

Bioxytran Stock Performance

Shares of BIXT opened at $0.15 on Friday. The stock has a market capitalization of $13.22 million, a P/E ratio of -15.00 and a beta of 2.00. The company’s fifty day moving average is $0.10 and its two-hundred day moving average is $0.10. Bioxytran has a 1 year low of $0.06 and a 1 year high of $0.21.

About Bioxytran

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.